Novo Nordisk A/S (NOVO-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novo Nordisk A/S (NOVO-B) has a cash flow conversion efficiency ratio of 0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr7.62 Billion ≈ $1.19 Billion USD) by net assets (Dkr194.05 Billion ≈ $30.36 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Novo Nordisk A/S (NOVO-B) defensive interval to measure how many days the company can operate on defensive assets alone.
Novo Nordisk A/S - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how Novo Nordisk A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novo Nordisk A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novo Nordisk A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deere & Company
NYSE:DE
|
-0.034x |
|
Charles Schwab Corp
NYSE:SCHW
|
0.177x |
|
BlackRock Inc
NYSE:BLK
|
-0.017x |
|
Industria de Diseno Textil SA
MC:ITX
|
0.178x |
|
Abbott Laboratories
NYSE:ABT
|
0.054x |
|
Gilead Sciences Inc
NASDAQ:GILD
|
0.147x |
|
Southern Copper Corporation
NYSE:SCCO
|
0.143x |
|
AT&T Inc.
NYSE:T
|
0.059x |
Annual Cash Flow Conversion Efficiency for Novo Nordisk A/S (1990–2025)
The table below shows the annual cash flow conversion efficiency of Novo Nordisk A/S from 1990 to 2025. For the full company profile with market capitalisation and key ratios, see Novo Nordisk A/S stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr194.05 Billion ≈ $30.36 Billion |
Dkr119.10 Billion ≈ $18.63 Billion |
0.614x | -27.20% |
| 2024-12-31 | Dkr143.49 Billion ≈ $22.45 Billion |
Dkr120.97 Billion ≈ $18.93 Billion |
0.843x | -17.51% |
| 2023-12-31 | Dkr106.56 Billion ≈ $16.67 Billion |
Dkr108.91 Billion ≈ $17.04 Billion |
1.022x | +8.16% |
| 2022-12-31 | Dkr83.49 Billion ≈ $13.06 Billion |
Dkr78.89 Billion ≈ $12.34 Billion |
0.945x | +21.54% |
| 2021-12-31 | Dkr70.75 Billion ≈ $11.07 Billion |
Dkr55.00 Billion ≈ $8.61 Billion |
0.777x | -5.24% |
| 2020-12-31 | Dkr63.33 Billion ≈ $9.91 Billion |
Dkr51.95 Billion ≈ $8.13 Billion |
0.820x | +1.00% |
| 2019-12-31 | Dkr57.59 Billion ≈ $9.01 Billion |
Dkr46.78 Billion ≈ $7.32 Billion |
0.812x | -5.62% |
| 2018-12-31 | Dkr51.84 Billion ≈ $8.11 Billion |
Dkr44.62 Billion ≈ $6.98 Billion |
0.861x | +4.14% |
| 2017-12-31 | Dkr49.81 Billion ≈ $7.79 Billion |
Dkr41.17 Billion ≈ $6.44 Billion |
0.826x | -22.57% |
| 2016-12-31 | Dkr45.27 Billion ≈ $7.08 Billion |
Dkr48.31 Billion ≈ $7.56 Billion |
1.067x | +30.93% |
| 2015-12-31 | Dkr46.97 Billion ≈ $7.35 Billion |
Dkr38.29 Billion ≈ $5.99 Billion |
0.815x | +3.64% |
| 2014-12-31 | Dkr40.29 Billion ≈ $6.30 Billion |
Dkr31.69 Billion ≈ $4.96 Billion |
0.787x | +29.06% |
| 2013-12-31 | Dkr42.57 Billion ≈ $6.66 Billion |
Dkr25.94 Billion ≈ $4.06 Billion |
0.609x | +11.47% |
| 2012-12-31 | Dkr40.63 Billion ≈ $6.36 Billion |
Dkr22.21 Billion ≈ $3.48 Billion |
0.547x | -4.21% |
| 2011-12-31 | Dkr37.45 Billion ≈ $5.86 Billion |
Dkr21.37 Billion ≈ $3.34 Billion |
0.571x | +7.21% |
| 2010-12-31 | Dkr36.97 Billion ≈ $5.78 Billion |
Dkr19.68 Billion ≈ $3.08 Billion |
0.532x | +23.71% |
| 2009-12-31 | Dkr35.73 Billion ≈ $5.59 Billion |
Dkr15.38 Billion ≈ $2.41 Billion |
0.430x | +10.31% |
| 2008-12-31 | Dkr33.06 Billion ≈ $5.17 Billion |
Dkr12.90 Billion ≈ $2.02 Billion |
0.390x | +25.74% |
| 2007-12-31 | Dkr32.22 Billion ≈ $5.04 Billion |
Dkr10.00 Billion ≈ $1.56 Billion |
0.310x | +20.76% |
| 2006-12-31 | Dkr30.13 Billion ≈ $4.71 Billion |
Dkr7.74 Billion ≈ $1.21 Billion |
0.257x | -18.51% |
| 2005-12-31 | Dkr27.59 Billion ≈ $4.32 Billion |
Dkr8.70 Billion ≈ $1.36 Billion |
0.315x | +10.07% |
| 2004-12-31 | Dkr26.69 Billion ≈ $4.18 Billion |
Dkr7.64 Billion ≈ $1.20 Billion |
0.286x | +17.27% |
| 2003-12-31 | Dkr25.29 Billion ≈ $3.96 Billion |
Dkr6.18 Billion ≈ $966.71 Million |
0.244x | +14.69% |
| 2002-12-31 | Dkr22.90 Billion ≈ $3.58 Billion |
Dkr4.88 Billion ≈ $762.97 Million |
0.213x | -0.77% |
| 2001-12-31 | Dkr20.08 Billion ≈ $3.14 Billion |
Dkr4.31 Billion ≈ $674.44 Million |
0.215x | -35.77% |
| 2000-12-31 | Dkr15.75 Billion ≈ $2.46 Billion |
Dkr5.26 Billion ≈ $823.26 Million |
0.334x | +71.52% |
| 1999-12-31 | Dkr18.63 Billion ≈ $2.91 Billion |
Dkr3.63 Billion ≈ $567.93 Million |
0.195x | +1.11% |
| 1998-12-31 | Dkr18.04 Billion ≈ $2.82 Billion |
Dkr3.48 Billion ≈ $543.78 Million |
0.193x | +15.51% |
| 1997-12-31 | Dkr18.17 Billion ≈ $2.84 Billion |
Dkr3.03 Billion ≈ $474.36 Million |
0.167x | +39.10% |
| 1996-12-31 | Dkr16.02 Billion ≈ $2.51 Billion |
Dkr1.92 Billion ≈ $300.66 Million |
0.120x | -31.64% |
| 1995-12-31 | Dkr14.42 Billion ≈ $2.26 Billion |
Dkr2.53 Billion ≈ $395.82 Million |
0.175x | -13.47% |
| 1994-12-31 | Dkr13.13 Billion ≈ $2.05 Billion |
Dkr2.66 Billion ≈ $416.62 Million |
0.203x | +26.76% |
| 1993-12-31 | Dkr11.95 Billion ≈ $1.87 Billion |
Dkr1.91 Billion ≈ $299.16 Million |
0.160x | +27.15% |
| 1992-12-31 | Dkr10.56 Billion ≈ $1.65 Billion |
Dkr1.33 Billion ≈ $207.76 Million |
0.126x | +0.76% |
| 1991-12-31 | Dkr9.50 Billion ≈ $1.49 Billion |
Dkr1.19 Billion ≈ $185.60 Million |
0.125x | -41.66% |
| 1990-12-31 | Dkr7.03 Billion ≈ $1.10 Billion |
Dkr1.50 Billion ≈ $235.32 Million |
0.214x | -- |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i… Read more